Attilio Iemolo1, Mariel Seiglie1,2, Angelo Blasio1, Pietro Cottone1, Valentina Sabino3. 1. Laboratory of Addictive Disorders, Department of Pharmacology and Experimental Therapeutics and Department of Psychiatry, Boston University School of Medicine, 72 E Concord St, R-612, Boston, MA, 02118, USA. 2. Graduate Program in Neuroscience, Boston University, Boston, MA, USA. 3. Laboratory of Addictive Disorders, Department of Pharmacology and Experimental Therapeutics and Department of Psychiatry, Boston University School of Medicine, 72 E Concord St, R-612, Boston, MA, 02118, USA. vsabino@bu.edu.
Abstract
RATIONALE: Anxiety disorders are the most common mental disorders in the USA. Characterized by feelings of uncontrollable apprehension, they are accompanied by physical, affective, and behavioral symptoms. The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor PAC1 (PAC1R) are highly expressed in the central nucleus of the amygdala (CeA), and they have gained growing attention for their proposed role in mediating the body's response to stress. OBJECTIVES: The aim of this study was to evaluate the anxiogenic effects of PACAP in the CeA and its effects on the hypothalamic-pituitary-adrenal (HPA) axis. Furthermore, the mechanism of action of PACAP in the CeA was investigated. METHODS: PACAP was microinfused into the CeA of rats, and its effects in the elevated plus maze (EPM), the defensive withdrawal tests, and plasma corticosterone levels were evaluated. The ability of the melanocortin receptor antagonist SHU9119 to block PACAP effect in the EPM was assessed. RESULTS: Intra-CeA PACAP exerted a dose-dependent anxiogenic effect and activated the HPA axis. In contrast, PACAP microinfused into the basolateral nucleus of the amygdala (BlA) had no effect. Finally, the anxiogenic effect of intra-CeA PACAP was prevented by SHU9119. CONCLUSIONS: These data prove an anxiogenic role for the PACAP system of the CeA and reveal that the melanocortin receptor 4 (MC4R) system of CeA mediates these effects. Our data provide insights into this neuropeptide system as a mechanism for modulating the behavioral and endocrine response to stress and suggest that dysregulations of this system may contribute to the pathophysiology of anxiety-related disorders.
RATIONALE: Anxiety disorders are the most common mental disorders in the USA. Characterized by feelings of uncontrollable apprehension, they are accompanied by physical, affective, and behavioral symptoms. The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor PAC1 (PAC1R) are highly expressed in the central nucleus of the amygdala (CeA), and they have gained growing attention for their proposed role in mediating the body's response to stress. OBJECTIVES: The aim of this study was to evaluate the anxiogenic effects of PACAP in the CeA and its effects on the hypothalamic-pituitary-adrenal (HPA) axis. Furthermore, the mechanism of action of PACAP in the CeA was investigated. METHODS:PACAP was microinfused into the CeA of rats, and its effects in the elevated plus maze (EPM), the defensive withdrawal tests, and plasma corticosterone levels were evaluated. The ability of the melanocortin receptor antagonist SHU9119 to block PACAP effect in the EPM was assessed. RESULTS: Intra-CeAPACAP exerted a dose-dependent anxiogenic effect and activated the HPA axis. In contrast, PACAP microinfused into the basolateral nucleus of the amygdala (BlA) had no effect. Finally, the anxiogenic effect of intra-CeAPACAP was prevented by SHU9119. CONCLUSIONS: These data prove an anxiogenic role for the PACAP system of the CeA and reveal that the melanocortin receptor 4 (MC4R) system of CeA mediates these effects. Our data provide insights into this neuropeptide system as a mechanism for modulating the behavioral and endocrine response to stress and suggest that dysregulations of this system may contribute to the pathophysiology of anxiety-related disorders.
Authors: Karen K Ryan; Joram D Mul; Christoffer Clemmensen; Ann E Egan; Denovan P Begg; Kristen Halcomb; Randy J Seeley; James P Herman; Yvonne M Ulrich-Lai Journal: Psychoneuroendocrinology Date: 2014-01-22 Impact factor: 4.905
Authors: K R Lezak; E Roelke; O M Harris; I Choi; S Edwards; N Gick; G Cocchiaro; G Missig; C W Roman; K M Braas; D J Toufexis; V May; S E Hammack Journal: Psychoneuroendocrinology Date: 2014-03-25 Impact factor: 4.905
Authors: Galen Missig; Carolyn W Roman; Margaret A Vizzard; Karen M Braas; Sayamwong E Hammack; Victor May Journal: Neuropharmacology Date: 2014-07-03 Impact factor: 5.250
Authors: Susan E Martelle; Evelin M Cotella; Nawshaba Nawreen; Carrie Chen; Benjamin A Packard; Maureen Fitzgerald; James P Herman Journal: Stress Date: 2021-03-17 Impact factor: 3.493
Authors: Sema G Quadir; Sean M Tanino; Yasmine N Sami; Margaret A Minnig; Malliga R Iyer; Kenner C Rice; Pietro Cottone; Valentina Sabino Journal: Alcohol Clin Exp Res Date: 2021-07-05 Impact factor: 3.928